Notícias

XPeng’s central valuation estimate has been reset, with Fair Value moving from US$22.36 to US$19.06. This change reframes how investors may think about potential upside in the stock. The wide spread in updated Street targets, now roughly between US$12 and US$24, reflects differing views on XPeng’s ability to balance growth plans, robotics optionality and the execution questions raised in recent research. As you read on, you will see how to track these shifting assumptions and follow the...

IonQ (NYSE: IONQ) and partners Oak Ridge National Laboratory, NVIDIA, and the University of Tennessee built a generative AI system that writes quantum optimization circuits. The joint team reports that the AI driven circuit synthesis cuts out manual trial and error tuning for complex quantum optimization tasks. The research, benchmarked at scale, received a best paper award at a major industry conference, signaling peer recognition of its impact. This new generative AI circuit writer is only...

GM is bringing Apple CarPlay and Android Auto back to its vehicles, reversing one of the more unpopular decisions in the automaker's recent history.

While it's challenging to be bullish, this industry-leading business has positive traits investors can appreciate.

Bill Ackman's Pershing Square Inc., a recent IPO, broke out past a buy point Friday in a rocky market.  The hedge fund billionaire's publicly traded investment vehicle, Pershing Square Inc., rallied an impressive 27% for the week after bullish analyst upgrades.

Carl Icahn keeps piling into his own holding company even as its units sink to multi-year lows, and the reasons behind his accumulation are far more complicated than a simple vote of confidence.

Robinhood stock surged in an end-of-week crypto rally. SpaceX is testing an aggressive entry. They lead five stocks near buy points.

Several tech and political leaders have called for a pause on the development of advanced AI. While that is wishful thinking at best, "AI loser" Adobe is a "Buy" anyway.

The Nvidia chief makes the case for engineering solutions—not new laws or industry speed bumps—to address AI safety concerns.

The food giant fell after Moscow placed its local operations under temporary external administration, reviving fears that another Western company could ultimately lose control of its Russian assets.

Motley Fool analysts share how to build a portfolio that gives back less ground when the market turns south.

Fast-growing funds can build your wealth surprisingly quickly.

The Fed raised rates 25 basis points on Sept. 16, and brokers and exchanges like Interactive Brokers, Robinhood, and CME Group stand to benefit from the new hiking cycle.

Fink said he was "on track to become CEO of the firm."

Capital Economics has outlined the potential consequences of a collapse in artificial intelligence-related stock valuations, forecasting substantial declines in global equities, limited gains in some government bonds and a weaker US dollar. In a note published this week, chief economic adviser John Higgins said he sees “plenty of signs that we are now in the late stages of a bubble in AI,” identifying the US equity market as the primary source of potential disruption.

Walmart's fundamentals and valuation don't suggest a quick run-up to $1 trillion.

It’s not a great time for real estate, but this has created some long-term opportunities.

Investor and entrepreneur Kevin O’Leary warned investors that excessive borrowing can quickly destroy the value of an otherwise strong investment when markets turn against them. O’Leary Warns About Investment Leverage On Wednesday, O’Leary said on X that excessive leverage is...

Investors are well aware of the risks, but they have simply decided none are significant enough to force them out of the market.

The pride of Cupertino continues its winning ways, and investors are eager to jump on the bandwagon.

SpaceX completed the largest IPO in history in June.

Fortinet has ridden a powerful share price run in recent years, which puts a sharp spotlight on whether the current US$169.84 level is adequately supported by the cash the business can generate. With expectations shaped by both strong historical returns and fresh corporate milestones, the question now is how the stock lines up against its own cash flow potential. Over the past 3 years the stock has returned 191.6%. This raises the stakes on whether that performance is reflected in the...

Aptiv’s fair value estimate has moved from US$78.21 to US$66.61, pointing to a reduced assessed upside compared with earlier models. This shift lines up with a split analyst narrative, where optimism around the post EDS separation mix and software exposure is balanced against caution on auto sector headwinds, execution questions and softer guidance. Read on to see how these views are shaping the evolving story around Aptiv and what to watch as new data comes through. Stay updated as the Fair...

Conference spotlight and why Hubbell is back on investor radar Hubbell (HUBB) steps into the spotlight as President and CEO Gerben W. Bakker speaks at Morgan Stanley's Laguna Conference. The appearance gives investors fresh commentary to measure against recent share performance. Recent trading tells a mixed story. Hubbell’s share price has eased over the past month, with a 30 day share price return of 6.04% in the red. By contrast, the 1 year total shareholder return of 2.48% and the 5 year...

Earlier this month, Vicor Corporation granted a non-exclusive license to a leading AI original equipment manufacturer for its patented Vertical Power Delivery (VPD) technology, allowing the OEM to source VPD modules from both Vicor and unlicensed suppliers. This licensing approach, combined with Vicor’s patented VPD architecture that tackles the “last inch problem” in powering high-performance AI processors, could materially influence how hyperscalers structure their power-delivery supply...

Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-world clinical and imaging records. Management targets scaling the platform to one million whole genomes tied to patient outcomes for use in drug development and personalized care. This new whole-genome sequencing and clinical data platform comes against a...

Money is flowing back into crypto ETFs, but which one is the best fit for your portfolio?

Despite Nvidia's growth, the return on such a modest investment may be surprising.

Here are Cathie Wood’s latest moves.

Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu